The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy.

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Drug Discovery Today

• Publication date

  2021-02-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2021.01.034PMID 33561465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy

  2020cited by this paper
• Cancer statistics, 2020

  2020cited by this paper
• Cancer Progress and Priorities: Prostate Cancer

  2020cited by this paper
• Testosterone therapy may reduce prostate cancer risk due to testosterone deficiency at a young age via stabilizing serum testosterone levels

  2020cited by this paper
• Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality

  2020cited by this paper
• Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men with Late-Onset Hypogonadism.

  2019cited by this paper
• Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study

  2019cited by this paper
• Higher serum testosterone levels predict poor prognosis in castration‐resistant prostate cancer patients treated with docetaxel

  2019cited by this paper
• Testosterone Therapy in Relation to Prostate Cancer in a U.S. Commercial Insurance Claims Database

  2019cited by this paper
• Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function

  2019cited by this paper
• Late‐onset hypogonadism: a concept comes of age

  2019cited by this paper
• Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location

  2018cited by this paper
• Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

  2018cited by this paper
• Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro‐oncologists' opinions and practice

  2018cited by this paper
• Bipolar androgen therapy: an intriguing paradox.

  2018cited by this paper
• Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

  2018cited by this paper
• Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

  2018cited by this paper
• Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register

  2017cited by this paper
• Testosterone inhibits the growth of prostate cancer xenografts in nude mice

  2017cited by this paper
• Testosterone therapy improves erectile function and libido in hypogonadal men

  2017cited by this paper
• Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men

  2017cited by this paper
• Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer

  2017cited by this paper
• Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.

  2016cited by this paper
• Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study

  2016cited by this paper
• Low testosterone level is an independent risk factor for high‐grade prostate cancer detection at biopsy

  2016cited by this paper
• Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate‐specific antigen (PSA) level: a meta‐analysis

  2016cited by this paper
• Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions.

  2016cited by this paper
• Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results

  2015cited by this paper
• Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.

  2015cited by this paper
• Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.

  2015cited by this paper
• Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study

  2015cited by this paper
• Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro

  2014cited by this paper
• Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men

  2014cited by this paper
• Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation

  2014cited by this paper
• Long‐acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer

  2014cited by this paper
• Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β‐catenin/TCF‐4 complex inhibition of c‐MYC transcription

  2014cited by this paper
• A new era of testosterone and prostate cancer: from physiology to clinical implications.

  2014cited by this paper
• Testosterone replacement therapy in the setting of prostate cancer treated with radiation

  2013cited by this paper
• Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.

  2013cited by this paper
• Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.

  2013cited by this paper
• Low serum testosterone levels are predictive of prostate cancer

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy

  2012cited by this paper
• Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

  2012cited by this paper
• Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment

  2012cited by this paper
• Adaptive auto‐regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer

  2012cited by this paper
• Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?

  2011cited by this paper
• Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

  2011cited by this paper
• Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements

  2010cited by this paper
• Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer

  2010cited by this paper
• Is a Decreased Serum Testosterone Level a Risk Factor for Prostate Cancer? A Cohort Study of Korean Men

  2010cited by this paper
• Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.

  2010cited by this paper
• Loss-of-Nkx3.1 Leads to Activation of Discrete Downstream Target Genes during Prostate Tumorigenesis

  2009cited by this paper
• Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

  2009cited by this paper
• Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

  2009cited by this paper
• Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes?

  2009cited by this paper
• A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.

  2009cited by this paper
• Testosterone replacement therapy following radical prostatectomy.

  2009cited by this paper
• Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

  2009cited by this paper
• Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial.

  2008cited by this paper
• Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

  2008cited by this paper
• The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes & Insulin Resistance Short Running Title: Testosterone deficiency, Insulin Resistance & Type 2 Diabetes

  2008cited by this paper
• Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications

  2008cited by this paper
• The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance.

  2008cited by this paper
• Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research

  2007cited by this paper
• Stabilizing Androgen Receptor in Mitosis Inhibits Prostate Cancer Proliferation

  2007cited by this paper
• ATP-dependent Assembly of the Human Origin Recognition Complex*♦

  2007cited by this paper
• Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells

  2006cited by this paper
• Forebrain gonadotropin-releasing hormone neuronal development: insights from transgenic medaka and the relevance to X-linked Kallmann syndrome.

  2006cited by this paper
• Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer

  2006cited by this paper
• Testosterone and prostate cancer: an historical perspective on a modern myth.

  2006cited by this paper
• CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis.

  2005cited by this paper
• Testosterone replacement therapy after primary treatment for prostate cancer.

  2005cited by this paper
• LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription

  2005cited by this paper
• Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era

  2005cited by this paper
• Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.

  2005cited by this paper
• Preventing re-replication of chromosomal DNA

  2005cited by this paper
• Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

  2004cited by this paper
• Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection.

  2003cited by this paper
• Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

  2001cited by this paper
• Testosterone dose-response relationships in healthy young men.

  2001cited by this paper
• Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men.

  1998cited by this paper
• Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates.

  1988cited by this paper
• A new procedure for the quantitation of nuclear and cytoplasmic androgen receptors.

  1981cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix

  2024cites this paper
• Emphasizing the Role of Multi-omics Approach to Increase Survival Rate of Breast and Prostate Cancer Patients

  2023cites this paper
• Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta‐analysis

  2023cites this paper
• Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire

  2023cites this paper
• Pros and cons of hormone replacement therapy

  2023cites this paper
• Testosterone therapy in prostate cancer: is it still a controversy?

  2022cites this paper
• Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy

  2022cites this paper
• The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer

  2022cites this paper
• Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment

  2021cites this paper
• Sympathetic signaling facilitates progression of neuroendocrine prostate cancer

  2021cites this paper
• RNA methylation and cancer treatment.

  2021cites this paper